Regulus Therapeutics (RGLS) Competitors $8.30 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$8.30 -0.01 (-0.06%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RGLS vs. LGND, FOLD, CLDX, MNKD, INVA, DVAX, NVAX, OPK, GERN, and ZBIOShould you be buying Regulus Therapeutics stock or one of its competitors? The main competitors of Regulus Therapeutics include Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), MannKind (MNKD), Innoviva (INVA), Dynavax Technologies (DVAX), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), and Zenas Biopharma (ZBIO). These companies are all part of the "biotechnology" industry. Regulus Therapeutics vs. Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics MannKind Innoviva Dynavax Technologies Novavax OPKO Health Geron Zenas Biopharma Regulus Therapeutics (NASDAQ:RGLS) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings. Which has more risk & volatility, RGLS or LGND? Regulus Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Do institutionals & insiders have more ownership in RGLS or LGND? 92.4% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 4.4% of Regulus Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has better earnings & valuation, RGLS or LGND? Ligand Pharmaceuticals has higher revenue and earnings than Regulus Therapeutics. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegulus TherapeuticsN/AN/A-$30.04M-$0.73-11.36Ligand Pharmaceuticals$181.49M12.17$52.15M-$7.12-16.08 Does the MarketBeat Community favor RGLS or LGND? Ligand Pharmaceuticals received 60 more outperform votes than Regulus Therapeutics when rated by MarketBeat users. Likewise, 70.39% of users gave Ligand Pharmaceuticals an outperform vote while only 63.33% of users gave Regulus Therapeutics an outperform vote. CompanyUnderperformOutperformRegulus TherapeuticsOutperform Votes49463.33% Underperform Votes28636.67% Ligand PharmaceuticalsOutperform Votes55470.39% Underperform Votes23329.61% Do analysts rate RGLS or LGND? Regulus Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 2.53%. Ligand Pharmaceuticals has a consensus price target of $146.14, suggesting a potential upside of 27.65%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Regulus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regulus Therapeutics 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.29Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor RGLS or LGND? In the previous week, Regulus Therapeutics had 5 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 9 mentions for Regulus Therapeutics and 4 mentions for Ligand Pharmaceuticals. Regulus Therapeutics' average media sentiment score of 1.26 beat Ligand Pharmaceuticals' score of 1.07 indicating that Regulus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regulus Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is RGLS or LGND more profitable? Ligand Pharmaceuticals has a net margin of 29.68% compared to Regulus Therapeutics' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 4.95% beat Regulus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Regulus TherapeuticsN/A -53.07% -48.58% Ligand Pharmaceuticals 29.68%4.95%4.39% SummaryLigand Pharmaceuticals beats Regulus Therapeutics on 13 of the 17 factors compared between the two stocks. Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGLS vs. The Competition Export to ExcelMetricRegulus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$573.95M$6.85B$5.57B$8.66BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-7.758.8827.3420.20Price / SalesN/A267.20415.29164.38Price / CashN/A65.8538.2534.64Price / Book7.906.727.174.73Net Income-$30.04M$143.74M$3.23B$248.00M7 Day Performance4.02%12.24%6.74%4.53%1 Month Performance5.34%21.46%15.54%10.88%1 Year Performance238.37%9.88%32.85%15.20% Regulus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGLSRegulus Therapeutics2.2796 of 5 stars$8.30flat$8.50+2.4%+272.2%$574.64MN/A-7.7630Positive NewsLGNDLigand Pharmaceuticals4.8205 of 5 stars$101.64-0.5%$146.14+43.8%+34.6%$1.96B$181.49M40.4980Positive NewsFOLDAmicus Therapeutics3.7199 of 5 stars$6.16+1.5%$16.22+163.3%-40.0%$1.90B$543.14M-34.22480CLDXCelldex Therapeutics1.9813 of 5 stars$19.97+1.0%$53.90+169.9%-41.3%$1.33B$7.56M-7.77150Positive NewsAnalyst RevisionMNKDMannKind3.0284 of 5 stars$4.29+3.4%$10.00+133.1%-6.4%$1.30B$297.60M61.29400Trending NewsAnalyst RevisionGap DownINVAInnoviva4.3992 of 5 stars$20.14+2.9%$55.00+173.1%+33.7%$1.26B$369.84M29.19100News CoverageHigh Trading VolumeDVAXDynavax Technologies4.4714 of 5 stars$9.84+0.5%$24.00+143.9%-14.8%$1.18B$294.62M54.67350News CoverageNVAXNovavax3.8192 of 5 stars$7.07-3.7%$19.00+168.7%-59.2%$1.15B$1.21B-3.131,990Positive NewsOPKOPKO Health4.528 of 5 stars$1.38+1.5%$2.75+99.3%+7.0%$1.09B$689.41M-7.264,200Positive NewsGERNGeron3.1032 of 5 stars$1.43-5.9%$5.06+254.0%-64.7%$910.79M$116.29M-4.4770ZBIOZenas Biopharma1.4325 of 5 stars$10.06+5.7%$36.67+264.5%N/A$420.85M$15M-2.83N/ATrending NewsHigh Trading Volume Related Companies and Tools Related Companies Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives Celldex Therapeutics Alternatives MannKind Alternatives Innoviva Alternatives Dynavax Technologies Alternatives Novavax Alternatives OPKO Health Alternatives Geron Alternatives Zenas Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGLS) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.It could very well mark the beginning of a new multitrillion-dollar industrial revolution. Up until now, we...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump Nominates “Next Elon”Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RGLS Stock Free RGLS Stock Alerts